Evidence Snapshot
Regulatory Context
Not FDA-approved in the U.S.; FDA identifies Selank acetate among compounded substances with unresolved safety and characterization concerns.
Research Takeaway
Selank is a separate seven-amino-acid synthetic tuftsin analog commonly represented as Thr-Lys-Pro-Arg-Pro-Gly-Pro. Selank must not be merged with N-acetyl Selank amidate, Selank acetate unless the source specifically identifies that form, or other modified or amidated variants.
See all 11 evidence claims →Quick Summary
Selank is a synthetic peptide-based compound often discussed for stress response, anxiety, and neuroprotective mechanisms. It has more regional history of use than many gray-market peptides, but U.S.-style FDA-approved indications for common anxiolytic claims are lacking. This page summarizes Selank's regulatory status, small/limited human evidence, preclinical findings, and anecdotal nootropic reports.
Mechanism & Research Overview
Selank is a synthetic heptapeptide derived from a tuftsin-related sequence with a Pro-Gly-Pro extension. Its best-characterized mechanistic theme is modulation of GABAergic signaling, but the evidence is primarily preclinical. Rat-brain membrane experiments found that Selank altered radiolabeled GABA binding in a concentration-dependent manner and behaved as a positive allosteric modulator in experimental receptor-binding systems. Gene-expression studies in rat brain also reported changes in transcripts involved in GABAergic neurotransmission after Selank administration. These findings provide a plausible mechanistic link to anxiety-related behavior, but they do not establish a defined human receptor mechanism.
Read more about the mechanism
Selank appears to have broader neurochemical effects than a single GABA pathway. Preclinical literature has reported changes involving serotonergic and dopaminergic systems, and behavioral studies in stress and disease models have described anxiolytic-like effects. In a 6-hydroxydopamine rat model of parkinsonism, Selank reduced anxiety-like behavior without improving the model's motor deficits. Other rodent experiments have explored interaction with benzodiazepines and stress-associated behavior. These observations support biological activity but remain model-dependent.
Immune and stress-response pathways have also been investigated. In a chronic social-stress rat model, Selank administration was associated with changes in circulating cytokines, including reductions toward control values for several pro-inflammatory mediators. This supports an immunomodulatory hypothesis but should not be presented as evidence of clinical anti-inflammatory efficacy.
Human evidence is limited but not absent. Small comparative studies in patients with generalized anxiety, phobic-anxiety, somatoform, and related disorders reported anxiolytic effects versus benzodiazepine-type comparators. A separate 2020 healthy-volunteer neuroimaging study comparing Selank, Semax, and placebo reported acute changes in resting-state connectivity involving the amygdala and temporal cortex. These findings justify describing Selank as having limited human evidence, while emphasizing that the literature is small, largely from a narrow research network, and lacks large independent multicenter confirmation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Selank is a separate seven-amino-acid synthetic tuftsin analog commonly represented as Thr-Lys-Pro-Arg-Pro-Gly-Pro. Selank must not be merged with N-acetyl Selank amidate, Selank acetate unless the source specifically identifies that form, or other modified or amidated variants.
Sources: FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
Small older studies, primarily from Russia, compared intranasal Selank with benzodiazepine-type drugs in patients described as having generalized anxiety disorder, neurasthenia, or anxiety-related conditions and reported possible reductions in anxiety symptoms. The evidence is limited by small sample sizes, limited methodological detail, older diagnostic terminology, uncertain randomization and blinding in some reports, unclear formulation identity, short follow-up, limited independent replication, and no FDA-reviewed efficacy program. These studies do not establish Selank as an approved or clinically validated treatment for anxiety, cognitive enhancement, sleep, depression, PTSD, or substance withdrawal.
Sources: Selank in generalized anxiety disorder and neurasthenia; Selank compared with phenazepam; Selank and phenazepam combination study
Supported
Selank safety is inadequately characterized. Important uncertainties include immunogenicity, aggregation and peptide impurities, unclear formulation identity, limited repeated-dose and long-term safety, unknown interactions with sedatives, anxiolytics, antidepressants, alcohol, or other neuroactive drugs, and route-specific sterility and endotoxin concerns. The absence of severe events in small studies does not establish general safety.
Sources: FDA Significant Safety Risks for Certain Compounded Bulk Substances; Selank in generalized anxiety disorder and neurasthenia
Supported
Selank is not a component of an FDA-approved drug and has no FDA-approved indication. FDA separately identifies Selank acetate among compounded substances that may present significant safety risks because of potential immunogenicity, aggregation, peptide-related impurities, and limited safety information.
Sources: FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
No FDA-approved Selank dosing regimen exists. Russian study regimens and compounding nominations must not be converted into consumer instructions.
Sources: FDA Evaluation of Semax-Related Bulk Drug Substances; FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
Preclinical receptor-binding and gene-expression studies suggest that Selank can modulate GABAergic signaling, including allosteric effects on GABA-related binding and changes in expression of genes involved in GABA neurotransmission.
Sources: Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity; Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Supported
In rodent stress models, Selank has altered anxiety-related behavior and cytokine patterns, but these findings do not establish clinical anxiolytic or anti-inflammatory efficacy.
Sources: The Influence of Selank on the Level of Cytokines Under the Conditions of Social Stress; Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Supported
Small comparative studies in anxiety-spectrum disorders have reported anxiolytic effects with Selank, including comparisons with medazepam or phenazepam, but the studies are small and come primarily from older Russian clinical literature.
Sources: Selank in generalized anxiety disorder and neurasthenia; A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders; Optimization of the treatment of anxiety disorders with the peptide anxiolytic Selank
Supported
A small healthy-volunteer neuroimaging study reported acute Selank-associated changes in resting-state functional connectivity involving the amygdala and temporal cortex; this is mechanistic imaging evidence rather than a clinical-outcome trial.
Supported
FDA states that compounded products containing Selank acetate may present immunogenicity concerns related to aggregation and peptide-related impurities, and that important human safety information remains lacking.
Sources: FDA Significant Safety Risks for Certain Compounded Bulk Substances
Supported
Existing Selank human studies do not establish effectiveness for broad claims involving cognition enhancement, depression, athletic performance, neurodegenerative disease, or other uses not directly tested in adequate clinical trials.
Sources: Selank in generalized anxiety disorder and neurasthenia; A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders; Optimization of the treatment of anxiety disorders with the peptide anxiolytic Selank; Functional connectomics of Selank/Semax
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Not FDA-approved in the U.S. for cognition, anxiety, depression, focus, or neuroenhancement claims.Safety Consideration
Human evidence varies by compound, region, language, and study quality.Safety Consideration
Anxiety, irritability, overstimulation, sedation, headache, nasal irritation, or sleep changes may be reported anecdotally.Safety Consideration
Psychiatric history, stimulant use, sedatives, antidepressants, and neurologic conditions require clinician caution.Safety Consideration
Product identity, nasal formulation quality, sterility, and dose consistency may vary outside regulated supply.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Functional connectomics of Selank/Semax (2020): Assessed effects of Selank and Semax on brain functional connectivity.
- Optimization of the treatment of anxiety disorders with the peptide anxiolytic Selank (2015):
- A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders (2014):
- Selank in generalized anxiety disorder and neurasthenia (2008): Discusses anxiolytic effects and mechanisms.
- Selank and phenazepam combination study ():
- Selank compared with phenazepam ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Functional connectomics of Selank/Semax | 2020 | Human neuroimaging study | Resting-state functional connectivity — Assessed effects of Selank and Semax on brain functional connectivity. | Human data; interpret within the studied population, dose, duration, and endpoints. Review full paper for adverse events and exclusions. | |
| Optimization of the treatment of anxiety disorders with the peptide anxiolytic Selank | 2015 | Anxiety disorder patients (human) | Additional Russian human anxiety-spectrum evidence examining treatment optimization with Selank. Limited by small sample size and geographic/language concentration. | ||
| A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders | 2014 | Anxiety disorder patients (human) | A small comparative Russian study reported anxiolytic effects of Selank versus phenazepam in anxiety disorders. Limited by small sample size and older reporting standards; not independently replicated at multicenter scale. | ||
| Selank in generalized anxiety disorder and neurasthenia | 2008 | Clinical/mechanistic | A small older study, primarily from Russia, compared intranasal Selank with a benzodiazepine-type drug in patients described as having generalized anxiety disorder or neurasthenia and reported possible reductions in anxiety symptoms. Limited by small sample size, limited methodological detail, older diagnostic terminology, uncertain randomization/blinding, unclear formulation identity, short follow-up, and no FDA-reviewed efficacy program. | Human data; interpret within the studied population, dose, duration, and endpoints. Review full paper for adverse events and exclusions. | |
| Selank and phenazepam combination study | A small older Russian study examined Selank combined with phenazepam. Same limitations as the other small Selank studies: small samples, limited methodological detail, uncertain formulation identity, short follow-up, no independent replication, no FDA-reviewed efficacy program. | ||||
| Selank compared with phenazepam | A small older Russian study compared intranasal Selank with phenazepam and described possible differences in sedation or cognition alongside anxiety-related effects. Same limitations as the other small Selank studies: small samples, limited methodological detail, uncertain formulation identity, short follow-up, no independent replication. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The Influence of Selank on the Level of Cytokines Under the Conditions of Social Stress | 2021 | Rat chronic social-stress model (preclinical) | In a chronic social-stress rat model, Selank administration was associated with changes in circulating cytokines, including reductions toward control values for several pro-inflammatory mediators. Supports an immunomodulatory hypothesis but is not evidence of clinical anti-inflammatory efficacy. | ||
| Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity | 2018 | Rat brain membrane preparations (analytical/preclinical) | Rat-brain membrane receptor-binding experiments found Selank altered radiolabeled GABA binding in a concentration-dependent manner and behaved as a positive allosteric modulator in experimental receptor-binding systems -- a mechanistic/analytical finding, not a human clinical mechanism. | ||
| Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats | 2017 | Rat unpredictable chronic mild stress model (preclinical) | In a rat unpredictable chronic mild stress model, Selank altered anxiety-related behavior and interacted with diazepam. A rodent behavioral-pharmacology finding, not evidence of human clinical anxiolytic efficacy. | ||
| Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission | 2016 | Animal/model study | Neurotransmission gene expression — Selank altered expression of neurotransmission-related genes. | Preclinical only; animal/cell findings do not establish human safety or efficacy. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FDA Significant Safety Risks for Certain Compounded Bulk Substances | 2026 | FDA separately identifies Selank acetate among compounded substances that may present significant safety risks because of potential immunogenicity, aggregation, peptide-related impurities, and limited safety information. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Nothing on this page is a mental-health treatment claim or a suggestion to use Selank for anxiety, depression, ADHD, stroke, or other cognitive disorders outside licensed clinician care.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-12.
Follow research updates for Selank
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.